linkedin post 2013-11-20 06:29:11

Uncategorized
$2.1 BILLION PHARMA SETTLEMENT. Teva and Sun Pharma will pay $2.15 billion to settle a patent suit related to its acid-reflux drug. "This is the first instance of generic drugmakers paying damages for marketing a copy of an existing drug for which patents have yet to expire (an 'at-risk' launch)." ""It is an important milestone, setting a 'book-end' case for the industry. It will serve to encourage patent settlements," " " http://lnkd.in/dHi9MEX View in LinkedIn
Read More

linkedin post 2013-11-17 07:25:28

Uncategorized
BOTS TO THE RESCUE. "The DARPA Robotics Challenge, by far the most ambitious and exciting large-scale robotics competition the world has ever seen, was largely inspired by the inability to avert disaster at Fukushima; that is not to say the response is due exclusively to Japan’s failure to secure a vital energy source, prevent a meltdown, or limit structural and environmental damage."" " http://lnkd.in/dxJwqhh View in LinkedIn
Read More

linkedin post 2013-11-17 07:21:06

Uncategorized
FUKUSHIMA'S ROBOT RENAISSANCE. "Events at Fukushima propelled practical development and funding almost immediately. Private companies such as Mitsubishi, Toshiba, Honda, Panasonic, and Toyota, most of which were already working with robotics, have now increased funding and investments of their proprietary expertise. Government agencies, including JAXA, NEDO, METI, have also increased or refocused support toward university robotics laboratories and private-public partnerships."" " http://lnkd.in/dxJwqhh View in LinkedIn
Read More

linkedin post 2013-11-19 06:18:36

Uncategorized
This simply proves that big companies with huge overheads are poor at innovation when measured by carrying costs. Small VC funded companies innovate successfully for a tiny fraction of the costs of big pharma. The urban myth perpetuates and big pharma likes that to support pricing decisions. http://lnkd.in/dWU3hVf View in LinkedIn
Read More

linkedin post 2013-11-19 05:53:51

Uncategorized
FTC TO CLARIFY PHARMA LITIGATION SETTLEMENTS. The Hatch-Waxman Act permits generic pharma to petition FDA that an innovator's patents are either invalid or that there is no infringement. "Some of these patent infringement suits are resolved by settlements that include a payment by the pioneer manufacturer to the generic manufacturer, which agrees to refrain from producing its generic drug for a specified period...these settlement agreements )are) "reverse payment agreements” or “pay-to-delay” agreements."" " http://www.lexology.com/library/detail.aspx?g=74fc4847-8d29-4cf5-9b15-a86c6cadf2c5 View in LinkedIn
Read More